Bayer is walking away from its alliance with Atara Biotherapeutics on two early-stage solid-tumor targeting CAR T-cell therapies, in a move that slims down a packed cell and gene therapy pipeline.
Atara’s shares have dipped on the news, as the deal first signed in 2020 with a $60m upfront payment...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

